Diarrhea during use of the oral angiogenesis inhibitors sunitinib and sorafenib

Diarrhea during use of the oral angiogenesis inhibitors sunitinib and sorafenib - Diarrhea during use of sunitinib and sorafenib

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35932

Enrollment

Registered

2011-08-23

Start date

2011-09-05

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GIST, hepatocellulair carcinoom of medullair schildkliercarcinoom diarrhea

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with renal cell carcinoma, GIST, hepatocellular carcinoma or medullary thyroid carcinoma treated with sunitinib or sorafenib Diarrhea CTC grade >= 1, generated during the use of angiogenesis inhibitor Age >= 18 years Signed informed consent

Exclusion criteria

Exclusion criteria: Known history of relevant disorders: absorption disorders such as inflammatory bowel disease, celiac disease or lactose intolerance Use of laxatives

Design outcomes

Primary

Measure	Time frame
Descriptive: from the outcomes of laboratory investigations, H2-breath test and scopies we hope to identify the cause of the diarrhea, e.g. secretoir, absorption failure or inflammation.	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results